Join Now!      Login

Whole Person Wellness Program Wellness Model
Skip Navigation Links
Health Centers
Key Services
Vitamin D Poll
Are you currently taking a Vitamin D supplement?

 Detection of Barbiturates in Urine: Detection of Barbiturates in Urine 
Toxicology Laboratories ©

Barbiturates have been known since 1864 when Dr. A. von Bayer synthesized barbituric acid. In 1903, barbital was introduced as a hypnotic for routine medicinal use. They were reclassified as Schedule 2 drugs in 1979 requiring a triplicate prescription to reduce the abuse of barbiturates. The benzodiazepines (Valium, Librium, Xanax) are generally safer in overdose and have largely replaced the use of barbiturates in medicinal pharmacology. Barbiturates are numerous, chemically derived from a common 2,4,6 trioxohexahydropyrimidine (barbituric acid) nucleus. Some of the common names are: phenobarbital (Luminol®), secobarbital (Seconal®), pentobarbital (Nembutal®), butalbital (Fiorinal®), amobarbital (Amytal®), and many others.

Pharmacological Effects
Barbiturates reversibly depress the activity of all excitable tissues. The use of phenobarbital in epilepsy, one of the few major remaining useful areas of barbiturate pharmacology, is due to its selective anticonvulsant activity depressing low frequency electrical activity in the cortex. Tolerance to barbiturates occurs with continued use. At first, a generalized sedative effect gives way to tolerance, especially toward effects on mood, sedation, and hypnosis. Like other central nervous system depressant drugs, barbiturates are abused and some individuals develop a dependence on them. Dependence upon and tolerance to barbiturates are closely related. The former, generating the drug seeking behavior that leads to increased usage and consequent higher levels of tolerance and hence the extent, duration, and continuity of abuse prior to withdrawal.

Laboratory Methods
Some labratories utilize immunoassay (EIA) for detecting barbiturates in urine. The immunoassays provide a cost effective, sensitive method for detection and reacts with a number of barbiturates. Gas chromatography/mass spectrometry (GC/MS) is used to further identify and confirm the presence of a particular barbiturate in the sample.

Cutoff and Detection Post Dose
The 200 ng/ml cutoff for the screening immunoassay allows detection of barbiturate use for up to 72 hours post dose. The cutoff level for GC/MS is 200 ng/ml for all barbiturate metabolites (amobarbital, butabarbital, butalbital, pentobarbital, phenobarbital, secobarbital). Various barbiturates have differing half lives of clearance post dose. For instance, the short acting barbiturate, secobarbital, has a half life of 29-34 hours, while phenobarbital, a long acting barbiturate, has a half life of 24-140 hours. Thus, use of phenobarbital may be detected much longer than secobarbital.

 Comments Add your comment 

 From Our Friends
Popular & Related Products
Popular & Featured Events
Error Reading Event Calendar
Stevia Products & Info
Dimensions of Wellness
Wellness, Feeling, dimension!

Home       Wellness       Health A-Z       Alternative Therapies       Find a Practitioner       Wellness Inventory
Healthy Kitchen       Healthy Woman       Healthy Man       Healthy Child       Healthy Aging       Wellness Center       Nutrition Center       Fitness Center
Stevia      Discount Lab Tests      First Aid      Global Health Calendar      Healthy Products       Privacy Policy     Contact Us
Disclaimer: The information provided on HealthWorld Online is for educational purposes only and IS NOT intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek professional medical advice from your physician or other qualified healthcare provider with any questions you may have regarding a medical condition.
Are you ready to embark on a personal wellness journey with our whole person approach?
Learn More/Subscribe
Are you looking to create or enhance a culture of wellness in your organization?
Learn More
Do you want to become a wellness coach?
Learn More
Free Webinar